{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"57.8","upperLimit":"68.4","value":"63.2"},{"groupId":"OG001","lowerLimit":"55.9","upperLimit":"66.5","value":"61.3"},{"groupId":"OG002","lowerLimit":"57.0","upperLimit":"67.6","value":"62.4"},{"groupId":"OG003","lowerLimit":"56.7","upperLimit":"67.3","value":"62.1"}]}],"title":"MCyR(n=334,336,335,335)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"85.4","upperLimit":"92.3","value":"89.2"},{"groupId":"OG001","lowerLimit":"86.5","upperLimit":"93.1","value":"90.2"},{"groupId":"OG002","lowerLimit":"88.5","upperLimit":"94.6","value":"91.9"},{"groupId":"OG003","lowerLimit":"83.4","upperLimit":"90.8","value":"87.5"}]}],"title":"CHR (n=334,336,335,335)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"334"},{"groupId":"OG001","value":"336"},{"groupId":"OG002","value":"335"},{"groupId":"OG003","value":"335"}],"units":"Participants"}],"description":"Complete cytogenetic response (CCyR): 0% Ph+ cells in metaphase in BM. Partial cytogenetic response (PCyR): \\>0 to 35% Ph+ cells in metaphase in BM. MCyR: best cytogenetic response of CCyR or PCyR. A complete hematologic response (CHR) was obtained when all the following criteria were met: White Blood Cells (WBC) ≤ institutional upper limit of normal (ULN); Platelets \\< 450,000/mm³; No blasts or promyelocytes in peripheral blood (PB); \\< 5% myelocytes plus metamyelocytes in PB; Basophils in PB \\< 20%; No extramedullary involvement (including no splenomegaly or hepatomegaly). Hematologic responses were counted anytime following 14 days after the dosing start date. No cytogenic assessments were made after 2 years of follow-up.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received either 100 mg or 140 mg once a day (QD) until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.","id":"OG000","title":"QD Dasatinib"},{"description":"Participants received either 50 mg or 70 mg twice a day (BID) until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.","id":"OG001","title":"BID Dasatinib"},{"description":"Participants received either 100 mg QD or 50 mg BID until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.","id":"OG002","title":"Total Daily Dose 100 mg"},{"description":"Participants received either 140 mg QD or 70 mg BID until progression of disease, development of intolerable toxicity, or the participant's decision to withdraw.","id":"OG003","title":"Total Daily Dose 140 mg"}],"paramType":"NUMBER","populationDescription":"All randomized participants were summarized.","reportingStatus":"POSTED","timeFrame":"24 months","title":"Percent of All Randomized Participants With Cytogenic and Hematologic Response by Dosing Schedule (QD or BID) and by Total Daily Dose (100 mg or 140 mg) at 24 Months Follow-Up","type":"SECONDARY","unitOfMeasure":"percentage of participants"}